Abstract
Background: Nitric oxide is important for the functional integrity of the vascular endothelium and is produced in endothelial cells by the enzyme endothelial nitric oxide synthase (eNOS). Hypertension has a strong genetic component, and the NOS3 gene, which encodes eNOS, represents an interesting candidate for contribution to the phenotype. The most clinically relevant polymorphisms in the NOS3 gene are a variable number tandem repeat (VNTR) in intron 4, and rs2070744 (T-786C) in the promoter region. Subjects and Methods: This study aims to investigate the association between these three polymorphisms in the NOS3 gene and modifier effect on age, progression of disease and hypertension in patients of ADPKD. Results: The present study carryout in the ADPKD patients admitted in NRI Medical College & Hospital. Univariate and multivariate logistic regression analyses were performed to assess the effect of genotypes and hypertension on the progress of chronic kidney disease (CKD). A stratified analysis was also performed to assess the evidence of the modification of hypertension-CKD relationship among VNTR genotypes. Conclusion: The results of this study indicated that the polymorphism in NOS3 may be a genetic susceptibility factor for hypertension in the Indian population.
- PDF — print-ready version
- 1. Hateboer N, v Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet. 1999;353:103-7.
- 2. Bergmann C, Kupper F, Schmitt CP, Vester U, Neuhaus TJ, Senderek J, et al. Multi-exon deletions of the PKHD1 gene cause autosomal recessive polycystic kidney disease (ARPKD). J Med Genet. 2005;42:e63.
- 3. Sharp AM, Messiaen LM, Page G, Antignac C, Gubler MC, Onuchic LF, et al. Comprehensive genomic analysis of PKHD1 mutations in ARPKD cohorts. J Med Genet. 2005;42:336-49.
- 4. Gabow PA. Autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993;22:511-2.
- 5. Chapin HC, Caplan MJ. The cell biology of polycystic kidney disease. J Cell Biol. 2010;191:701-10.
- 6. Terryn S, Ho A, Beauwens R, Devuyst O. Fluid transport and cystogenesis in autosomal dominant polycystic kidney disease. Biochim Biophys Acta. 2011;1812:1314-21.
- 7. Gabow PA, Duley I, Johnson AM. Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1992;20:140-3.
- 8. World Health Organization. Global status report on non communicable diseases 2010. Geneva: World Health Organization; 2011.
- 9. Persu A, Stoenoiu MS, Messiaen T et al. Modifier effect ofENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 2002; 11: 229–241
- 10. Mendelsohn ME, Karas RH. The protective effects of estrogenon the cardiovascular system. N Engl J Med 1999; 340: 1801–1811. 11. Noiri E, Satoh H, Taguchi J et al. Association of eNOSGlu298Asp polymorphism with end-stage renal disease.Hypertension 2002; 40: 535–540
- 12. Fischmann TO, Hruza A, Niu XD et al. Structuralcharacterization of nitric oxide synthase isoforms revealsstriking active-site conservation. Nat Struct Biol 1999; 6: 233–242
- 13. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP,Moss J. Intracellular processing of endothelial nitric oxidesynthase isoforms associated with differences in severity ofcardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 2000;97: 2832–2835
- 14. Fairchild TA, Fulton D, Fontana JT, Gratton JP, McCabe TJ,Sessa WC. Acidic hydrolysis as a mechanism for the cleavageof the Glu(298)!Asp variant of human endothelial nitric-oxide synthase. J Biol Chem 2001; 276: 26674–26679.
- 15. Luscher TF, Noll G. Is it all in the genes...? Nitric oxide synthase and coronary vasospasm. Circulation 1999; 99: 2855–2857.
- Patients of ADPKD
- 16. Ruschitzka F, Corti R, Noll G, Luscher TF. A rationale fortreatment of endothelial dysfunction in hypertension.J Hypertens 1999; 17: S25–S35.
- 17. Chapman AB, et al., Adv Chronic Kidney Dis, 2010;17:153–63. 18. Ecder T, et al., J Am Soc Nephrol, 2001;12:194–200. 19. Schrier RW, et al., Kidney Int, 2003;64:1792–9
- 20. Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama M, et al. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 1998;32(1):3-8.
- 21. Benjafield AV, Morris BJ. Association analyses of endothelial nitric oxide synthase gene polymorphisms in essential hypertension. Am J Hypertens 2000;13(9):994-8.
- 22. Li R, Lyn D, Lapu-Bula R, Oduwole A, Igho-Pemu P, Lankford B, et al. Relation of endothelial nitric oxide synthase gene to plasma nitric oxide level, endothelial function, and blood pressure in African Americans. Am J Hypertens 2004;17(7):560-7.
- 23. Patkar S, Charita BH, Ramesh C, Padma T. High risk of essential hypertension in males with intron 4 VNTR polymorphism of eNOS gene. Indian J Hum Genet 2009;15(2):49-53.
- 24. Persu A, Vinck WJ, El Khattabi O, Janssen RG, Paulussen AD, Devuyst O, et al. Influence of the endothelial nitric oxide synthase gene on conventional and ambulatory blood pressure: sib-pair analysis and haplotype study. J Hypertens 2005;23(4):759-65.
- 25. Merta M, Reiterova J, Tesar V, Stekrova J, Viklicky O. Influence of the endothelial nitric oxide synthase polymorphism on the progression of autosomal dominant polycystic kidney disease and IgA
- nephropathy. Ren Fail 2002;24(5):585-93.
- 26. Persu A, Stoenoiu MS, Messiaen T, Davila S, Robino C, El-Khattabi O, et al. Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 2002;11(3):229-41.
- 27. Azurmendi P, Fraga A, Muchnik C, Dos Ramos Farias M, Galan F, Guerra D, et al. [Progression of autosomic dominant polycystic kidney disease. Influence of endothelial NO synthase (ecNOS) and renin angiotensin system gene polymorphisms]. Medicina (B Aires) 2004;64(2):139-42.
- 28. Asakimori Y, Yorioka N, Taniguchi Y, Ito T, Ogata S, Kyuden Y, Kohno N.T(-786)–>C polymorphism of the endothelial nitric oxide synthase geneinfluences the progression of renal disease. Nephron. 2002;91(4):747–51.
- 29. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Ogawa H, Kugiyama K,Mizuno Y, Harada E, Nakamura S, Ito T, et al. T(-786)– > C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associatedwith myocardial infarction, especially without coronary organic stenosis. AmJ Cardiol. 2000;86(6):628–34.
- 30. Yoshimura M, Yasue H, Nakayama M, Shimasaki Y, Ogawa H, Kugiyama K,Saito Y, Miyamoto Y, Ogawa Y, Kaneshige T, et al. Genetic risk factors forcoronary artery spasm: significance of endothelial nitric oxide synthasegene T-786–>C and missense Glu298Asp variants. J Investig Med. 2000;48(5):367–74.
- 31. Jeerooburkhan N, Jones LC, Bujac S, Cooper JA, Miller GJ, Vallance P,Humphries SE, Hingorani AD. Genetic and environmental determinants ofplasma nitrogen oxides and risk of ischemic heart disease. Hypertension.2001;38(5):1054–61.
Looking up citing articles…